A structure-based framework for selective inhibitor design and optimization

被引:0
|
作者
Yurong Zou [1 ]
Tao Guo [1 ]
Zhiyuan Fu [1 ]
Zhongning Guo [1 ]
Weichen Bo [1 ]
Dengjie Yan [2 ]
Qiantao Wang [2 ]
Jun Zeng [3 ]
Dingguo Xu [4 ]
Taijin Wang [5 ]
Lijuan Chen [1 ]
机构
[1] Sichuan University,State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital
[2] Sichuan University,Key Laboratory of Drug
[3] University of Melbourne,Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, West China School of Pharmacy
[4] Sichuan University,Western Health, Faculty of Medicine Dentistry and Health Sciences
[5] Chengdu Zenitar Biomedical Technology Co.,MOE Key Laboratory of Green Chemistry and Technology, College of Chemistry
[6] Ltd.,undefined
关键词
D O I
10.1038/s42003-025-07840-3
中图分类号
学科分类号
摘要
Structure-based drug design aims to create active compounds with favorable properties by analyzing target structures. Recently, deep generative models have facilitated structure-specific molecular generation. However, many methods are limited by inadequate pharmaceutical data, resulting in suboptimal molecular properties and unstable conformations. Additionally, these approaches often overlook binding pocket interactions and struggle with selective inhibitor design. To address these challenges, we developed a framework called Coarse-grained and Multi-dimensional Data-driven molecular generation (CMD-GEN). CMD-GEN bridges ligand-protein complexes with drug-like molecules by utilizing coarse-grained pharmacophore points sampled from diffusion model, enriching training data. Through a hierarchical architecture, it decomposes three-dimensional molecule generation within the pocket into pharmacophore point sampling, chemical structure generation, and conformation alignment, mitigating instability issues. CMD-GEN outperforms other methods in benchmark tests and controls drug-likeness effectively. Furthermore, CMD-GEN excels in cases across three synthetic lethal targets, and wet-lab validation with PARP1/2 inhibitors confirms its potential in selective inhibitor design.
引用
收藏
相关论文
共 50 条
  • [31] Optimization of an α-aminonaphthylmethylphosphonic acid inhibitor of purple acid phosphatase using rational structure-based design approaches
    Feder, Daniel
    Mohd-Pahmi, Siti Hajar
    Adibi, Hadi
    Guddat, Luke W.
    Schenk, Gerhard
    McGeary, Ross P.
    Hussein, Waleed M.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 254
  • [32] Structure-based design of selective calpain-2 inhibitors
    Luo, Yun
    Chatterjee, Payal
    Alsamarah, Abdelaziz
    Kent, David
    Baudry, Michel
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [33] Structure-based design of selective nuclear hormone receptor ligands
    Magolda, RL
    Fensome, A
    Harnish, D
    Harris, HA
    Keith, JC
    Malamas, MS
    Manas, E
    Mewshaw, RE
    Olland, A
    Somers, WS
    Steffan, RJ
    Trybulski, EJ
    Unwalla, RJ
    Winneker, RC
    Wrobel, L
    Xu, ZB
    Zhang, PW
    Zhang, Z
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2639 - U2640
  • [34] Structure-based drug design of selective 5′-nucleotidases inhibitors
    Pachl, P.
    Brynda, J.
    Rosenberg, I.
    Fabry, M.
    Rezacova, P.
    FEBS JOURNAL, 2009, 276 : 159 - 159
  • [35] Structure-based drug design of selective 5'-nucleotidases inhibitors
    Pachl, Petr
    Brynda, Jiri
    Rosenberg, Ivan
    Fabry, Milan
    Rezacova, Pavlina
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2011, 67 : C227 - C228
  • [36] Structure-Based Design of Potent and Selective Inhibitors of Pyruvate Carboxylase
    Schneider, Nicholas
    Burkett, Daniel
    Wyatt, Brittney
    Mews, Mallory
    Bautista, Anson
    Engel, Ryan
    Dockendorff, Chris
    Donaldson, William
    St Maurice, Martin
    PROTEIN SCIENCE, 2021, 30 : 141 - 141
  • [37] Structure-based design of estrogen receptor-β selective ligands
    Manas, ES
    Unwalla, RJ
    Xu, ZB
    Malamas, MS
    Miller, CP
    Harris, HA
    Hsiao, C
    Akopian, T
    Hum, WT
    Malakian, K
    Wolfrom, S
    Bapat, A
    Bhat, RA
    Stahl, ML
    Somers, WS
    Alvarez, JC
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (46) : 15106 - 15119
  • [38] Structure-based design
    Charlotte Harrison
    Nature Reviews Drug Discovery, 2011, 10 : 658 - 658
  • [39] Structure-based design
    Harrison, Charlotte
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (09) : 658 - 658
  • [40] Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)
    Cheng, Hengmiao
    Orr, Suvi T. M.
    Bailey, Simon
    Brooun, Alexei
    Chen, Ping
    Deal, Judith G.
    Deng, Yali L.
    Edwards, Martin P.
    Gallego, Gary M.
    Grodsky, Neil
    Huang, Buwen
    Jalaie, Mehran
    Kaiser, Stephen
    Kania, Robert S.
    Kephart, Susan E.
    Lafontaine, Jennifer
    Ornelas, Martha A.
    Pairish, Mason
    Planken, Simon
    Shen, Hong
    Sutton, Scott
    Zehnder, Luke
    Almaden, Chau D.
    Bagrodia, Shubha
    Falk, Matthew D.
    Gukasyan, Hovhannes J.
    Ho, Caroline
    Kang, Xiaolin
    Kosa, Rachel E.
    Liu, Ling
    Spilker, Mary E.
    Timofeevski, Sergei
    Visswanathan, Ravi
    Wang, Zhenxiong
    Meng, Fanxiu
    Ren, Shijian
    Shao, Li
    Xu, Feng
    Kath, John C.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (01) : 644 - 661